Nefazodone and depression

Drugs of Today

Volumn 34, Issue 10, 1998, Pages 845-853

  Vieweg, W Victor R ^a,b  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOXETINE; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ANXIETY NEUROSIS; ASTHENIA; CLINICAL TRIAL; CONFUSION; CONSTIPATION; DEPRESSION; DRUG ABSORPTION; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; HUMAN; HYPOTENSION; LONG TERM CARE; NAUSEA; ORAL DRUG ADMINISTRATION; REVIEW; SLEEP; SOMNOLENCE; VERTIGO; WITHDRAWAL SYNDROME; XEROSTOMIA;

EID: 0032444040     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.1998.34.10.487471     Document Type: Review

References (25)

1. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. American Psychiatric Association: Washington, DC 1994.
2. Katon, W. The epidemiology of depression in medical care. Int J Psychiatry Med 1987, 17: 93-112.
3. Holden, C. Depression: The news isn't depressing. Science 1991, 254: 1450-2.
4. Guze, S.B., Robins, E. Suicide and primary affective disorders. Br J Psychiatry 1970, 117: 437-8.
5. Johnson, J., Weissman, M., Klerman, G.L. Service utilization and social morbidity associated with depressive symptoms in the community. JAMA 1992, 267: 1478-83.
6. Elkin, I., Shea, M.T., Watkins, J.T. et al. National Institute of Mental Health Treatment of Depression Collaborative Research Program: General effectiveness of treatments. Arch Gen Psychiatry 1989, 46: 971-82.
7. Maes, M., Meltzer, H.Y. The serotonin hypothesis of major depression. In: Psychopharmacology: The Fourth Generation of Progress. Bloom, F.E., Kupfer, D.J. (Eds.). Raven Press: New York 1995, 933-44.
8. Golden, R.N. Selective serotonin reuptake inhibitor elimination half-lives: The long and short of it. Biol Psychiatry 1998, 44: 75-6.
9. Zajecka, J., Tracy, K.A., Mitchell, S. Discontinuation symptoms after treatment with serotonin reuptake inhibitors: A literature review. J Clin Psychiatry 1997, 58: 291-7.
10. Rosenbaum, J.F., Fava, M., Hoog, S.L., Ascroft, R.C., Krebs, W.B. Selective serotonin reuptake inhibitor discontinuation syndrome: A randomized clinical trial. Biol Psychiatry 1998, 44: 77-87.
11. Berber, M.J. FINISH: Remembering the discontinuation syndrome. J Clin Psychiatry 1998, 59: 255.
12. Giakas, W.J., Davis, J.M. Intractable withdrawal from venlafaxine treated with fluoxetine. Psychiatr Ann 1997, 27: 85-92.
13. Rickels, K., Schweizer, E., Clary, C., Fox, I., Weise, C. Nefazodone and imipramine in major depression: A placebo-controlled trial. Br J Psychiatry 1994, 164: 802-5.
14. Fontaine, R., Ontiveros, A., Elie, R. et al. A double-blind comparison of nefazodone, imipramine, and placebo in major depression. J Clin Psychiatry 1994, 55: 234-41.
15. Baldwin, D.S., Hawley, C.J., Abed, R.T. et al. A multicenter double-blind comparison of nefazodone and paroxetine in the treatment of outpatients with moderate-to-severe depression. J Clin Psychiatry 1996, 57(Suppl. 2): 46-52.
16. Feiger, A., Kiev, A., Shrivastava, R.K., Wisselink, P.G., Wilcox, C.S. Nefazodone versus sertraline in outpatients with major depression: Focus on efficacy, tolerability, and effects on sexual function and satisfaction. J Clin Psychiatry 1996, 57 (Suppl. 2): 53-62.
17. Cohn, C.K., Robinson, D.S., Roberts, D.L., Schwiderski, U.E., O'Brien, K., Ieni, J.R. Responders to antidepressant drug treatment: A study comparing nefazodone, imipramine, and placebo in patients with major depression. J Clin Psychiatry 1996, 57 (Suppl. 2): 15-8.
18. Robinson, D.S., Marcus, R.N., Archibald, D.G., Hardy, S.A. Therapeutic dose range of nefazodone in the treatment of major depression. J Clin Psychiatry 1996, 57 (Suppl. 2): 6-9.
19. Robinson, D.S., Roberts, D.L., Smith, J.M. et al. The safety profile of nefazodone. J Clin Psychiatry 1996, 57 (Suppl. 2): 31-8.
20. Zajecka, J.M. The effect of nefazodone on comorbid anxiety symptoms associated with depression: Experience in family practice and psychiatric outpatient settings. J Clin Psychiatry 1996, 57 (Suppl. 2): 10-4.
21. Rush, J.A., Armitage, R., Gillin, J.C. et al. Comparative effects of nefazodone and fluoxetine on sleep in outpatients with major depressive disorder. Biol Psychiatry 1998, 44: 3-14.
22. Marcus, R.N., Mendels, J. Nefazodone in the treatment of severe, melancholic, and recurrent depression. J Clin Psychiatry 1996, 57 (Suppl. 2): 19-23.
23. Feighner, J.P., Targum, S.D., Bennett, M.E. et al. A double-blind, placebo-controlled trial of nefazodone in the treatment of patients hospitalized with major depression. J Clin Psychiatry 1998, 59: 253.
24. Montgomery, S.A. Efficacy in long-term treatment of depression. J Clin Psychiatry 1996, 57 (Suppl. 2): 24-30.
25. Anton, S.F., Robinson, D.S., Roberts, D.L., Kensler, T.T., English, P.A., Archibald, D.G. Long-term treatment of depression with nefazodone. Psychopharmacol Bull 1994, 30: 165-9.